Summary

Similasan AG is precautionarily recalling batch 17911 of Similasan Sleep Disorder Globules (15g) from the market. The recall is being conducted in consultation with Swissmedic, as glass splinters were detected in a subsequent batch during quality assurance. Although no contamination has been detected in the affected batch 17911 to date, contamination cannot be completely ruled out. Affected consumers should not use the product and should return it to their point of purchase.

Persons

  • Similasan AG (Manufacturing company)
  • Swissmedic (Swiss Institute for Therapeutic Products)

Topics

  • Product recall
  • Quality assurance
  • Pharmaceutical safety
  • Glass splinter contamination

Clarus Lead

Similasan AG is conducting a precautionarily announced recall after foreign bodies were discovered in a subsequent product batch during internal quality inspections. Although the affected batch 17911 itself has shown no irregularities to date, the risk of possible contamination is assessed as not entirely excludable. Consumers have clear instructions: return the product to pharmacies, drugstores, or medical practices.

Detailed Summary

The recall affects exclusively batch 17911 of the product Similasan Sleep Disorder Globules in the 15-gram package size. The reason for the precautionary measure lies in the discovery of glass splinters during the manufacture of a subsequent batch. This quality defect scenario led to the conservative decision to also remove the previous batch from circulation, as cross-contamination cannot be ruled out with absolute certainty.

Affected persons are requested not to use packages with batch number 17911 and to return them immediately to their point of purchase (pharmacy, drugstore, or medical practice). For inquiries, the customer service of Similasan AG is available by telephone at +41 56 649 90 50 or by email ([email protected]).

Key Statements

  • Precautionarily announced recall of batch 17911 of Similasan Sleep Disorder Globules (15g)
  • Reason: Glass splinters discovered in subsequent batch; contamination risk not excluded
  • Consumers should not use the product and return it to their point of purchase
  • Recall conducted in consultation with the Swiss Institute for Therapeutic Products (Swissmedic)

Critical Questions

  1. Data Quality: How many packages of batch 17911 are estimated to still be in circulation, and how is the return rate being monitored?

  2. Contamination Mechanism: How did glass splinters technically arise in the subsequent batch, and which production steps were reviewed?

  3. Causality: On what basis is the contamination risk for batch 17911 assessed as not excludable when no contamination has been detected there to date?

  4. Timeline: Since when has the affected batch 17911 been distributed, and how long was it available on the market?

  5. Feasibility: How is it ensured that consumers receive the recall information, particularly if the product has already been used?

  6. Side Effects: Are there documented cases of injuries or complaints in connection with this batch?

Source Directory

Primary Source: Swissmedic Press Release: Similasan AG Recalls Sleep Disorder Globules Batch 17911 – February 5, 2026

Supplementary Sources:

  1. Swissmedic – Batch Recall Similasan Sleep Disorder Globules

Verification Status: ✓ February 5, 2026

This text was created with the support of an AI model. Editorial Responsibility: clarus.news | Fact-Check: February 5, 2026